{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:36Z","timestamp":1790755656655,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40265-018-0875-9","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T09:53:11Z","timestamp":1518429191000},"page":"367-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Eculizumab: A Review in Generalized Myasthenia Gravis"],"prefix":"10.1007","volume":"78","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"issue":"2","key":"875_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","volume":"37","author":"E Tuzun","year":"2011","unstructured":"Tuzun E, Huda R, Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun. 2011;37(2):136\u201343.","journal-title":"J Autoimmun."},{"issue":"8","key":"875_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol."},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol."},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90\u2013100.","journal-title":"J Autoimmun."},{"issue":"5","key":"875_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427\u201338.","journal-title":"Expert Rev Clin Immunol."},{"key":"875_CR6","unstructured":"National Institute of Neurological Disorders and Stroke. Myasthenia gravis fact sheet. 2017. https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Myasthenia-Gravis-Fact-Sheet#3. Accessed 8 Jan 2018."},{"issue":"3","key":"875_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","volume":"175","author":"JP Sieb","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408\u201318.","journal-title":"Clin Exp Immunol."},{"issue":"4","key":"875_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1515\/revneuro-2014-0021","volume":"25","author":"R Huda","year":"2014","unstructured":"Huda R, Tuzun E, Christadoss P. Targeting complement system to treat myasthenia gravis. Rev Neurosci. 2014;25(4):575\u201383.","journal-title":"Rev Neurosci."},{"key":"875_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis: results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.","journal-title":"Health Qual Life Outcomes."},{"issue":"4","key":"875_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378.","journal-title":"J Clin Neuromuscul Dis."},{"issue":"2","key":"875_CR11","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255\u201360.","journal-title":"Yale J Biol Med."},{"issue":"4","key":"875_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology."},{"issue":"5","key":"875_CR13","first-page":"267","volume":"52","author":"AG Engel","year":"1977","unstructured":"Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267\u201380.","journal-title":"Mayo Clin Proc."},{"issue":"6","key":"875_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","volume":"43","author":"S Nakano","year":"1993","unstructured":"Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology. 1993;43(6):1167\u201372.","journal-title":"Neurology."},{"issue":"12","key":"875_CR15","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","volume":"179","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Gong B, Lin F, et al. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007;179(12):8562\u20137.","journal-title":"J Immunol."},{"key":"875_CR16","unstructured":"Alexion Pharmaceuticals Inc. Soliris (eculizumab): US prescribing information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125166s422lbl.pdf. Accessed 10 Nov 2017."},{"key":"875_CR17","unstructured":"Alexion Europe SAS. Soliris (eculizumab): summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000791\/WC500054208.pdf. Accessed 11 Nov 2017."},{"key":"875_CR18","unstructured":"Japan Ministry of Health Labour and Welfare. Soliris (eculizumab): Japanese prescribing information. 2017. http:\/\/wwwhourei.mhlw.go.jp\/hourei\/doc\/tsuchi\/T171226I0050.pdf. Accessed 10 Jan 2018."},{"issue":"18","key":"875_CR19","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73(18):2053\u201366.","journal-title":"Drugs."},{"issue":"17","key":"875_CR20","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2165\/11208300-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327\u201345.","journal-title":"Drugs."},{"issue":"17\u201318","key":"875_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17\u201318):1389\u2013401.","journal-title":"Mol Immunol."},{"issue":"1","key":"875_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4049\/jimmunol.1600280","volume":"197","author":"JA Schatz-Jakobsen","year":"2016","unstructured":"Schatz-Jakobsen JA, Zhang Y, Johnson K, et al. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197(1):337\u201344.","journal-title":"J Immunol."},{"issue":"Suppl 1","key":"875_CR23","first-page":"S87","volume":"97","author":"C Lathia","year":"2015","unstructured":"Lathia C, Gao X, Kassir N, et al. Population pharmacokinetic and pharmacodynamic analysis of eculizumab to support phase III dosing regimen in patients with refractory generalized myasthenia gravis [abstract no. PII-091]. Clin Pharmacol Ther. 2015;97(Suppl 1):S87.","journal-title":"Clin Pharmacol Ther."},{"key":"875_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1.","journal-title":"Lancet Neurol."},{"issue":"3","key":"875_CR25","first-page":"106","volume":"56","author":"J Howard","year":"2017","unstructured":"Howard J, Wang JJ, O\u2019Brien F, et al. Efficacy of eculizumab on myasthenia gravis-activities of daily living and its respiratory, bulbar, limb and ocular domains in patients with ACHR+ refractory generalized myasthenia gravis [abstract no. 210 and poster]. Muscle Nerve. 2017;56(3):106.","journal-title":"Muscle Nerve."},{"issue":"1","key":"875_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard Jr","year":"2013","unstructured":"Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76\u201384.","journal-title":"Muscle Nerve."},{"key":"875_CR27","unstructured":"European Medicines Agency. Soliris (eculizumab): CHMP extension of indication variation assessment report. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000791\/WC500233876.pdf. Accessed 10 Nov 2017."},{"key":"875_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","volume":"1274","author":"S Muppidi","year":"2012","unstructured":"Muppidi S. The myasthenia gravis: specific activities of daily living profile. Ann NY Acad Sci. 2012;1274:114\u20139.","journal-title":"Ann NY Acad Sci."},{"issue":"5","key":"875_CR29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","volume":"49","author":"HD Katzberg","year":"2014","unstructured":"Katzberg HD, Barnett C, Merkies IS, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):661\u20135.","journal-title":"Muscle Nerve."},{"key":"875_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","volume":"1274","author":"TM Burns","year":"2012","unstructured":"Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann NY Acad Sci. 2012;1274:99\u2013106.","journal-title":"Ann NY Acad Sci."},{"issue":"2","key":"875_CR31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mus.21609","volume":"41","author":"TM Burns","year":"2010","unstructured":"Burns TM, Grouse CK, Conaway MR, et al. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219\u201326.","journal-title":"Muscle Nerve."},{"key":"875_CR32","unstructured":"Howard J, O\u2019Brien F, Wang JJ, et al. Dual responder analyses of both muscle strength and activities of daily living, eculizumab versus placebo, in refractory generalized myasthenia gravis (gMG) patients: results from the REGAIN study [abstract no. 012]. Neurology. 2017;88(19 Suppl)."},{"issue":"Supp 1","key":"875_CR33","first-page":"498","volume":"24","author":"H Andersen","year":"2017","unstructured":"Andersen H, Mantegazza R, Derosier F, et al. Eculizumab improves fatigue in patients with refractory generalized myasthenia gravis in the REGAIN study [abstract no. PR1094]. Eur J Neurol. 2017;24(Supp 1):498.","journal-title":"Eur J Neurol."},{"issue":"Supp 1","key":"875_CR34","first-page":"498","volume":"24","author":"H Andersen","year":"2017","unstructured":"Andersen H, Mantegazza R, Derosier F, et al. Correlation of neuro-QOL with MG-ADL, QMG, and MG-QOL15 in assessing the spectrum of disease in patients with refractory generalised myasthenia gravis in the REGAIN study [abstract no. PR1095]. Eur J Neurol. 2017;24(Supp 1):498\u20139.","journal-title":"Eur J Neurol."},{"issue":"3","key":"875_CR35","first-page":"106","volume":"56","author":"J Howard","year":"2017","unstructured":"Howard J, Wang JJ, O\u2019Brien F, et al. Efficacy of eculizumab is maintained beyond 26\u00a0weeks in patients with AChR+ refractory generalized myasthenia gravis [abstract no. 211 plus poster]. Muscle Nerve. 2017;56(3):106.","journal-title":"Muscle Nerve."},{"issue":"3","key":"875_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists\u2019 management guidelines. Pract Neurol. 2015;15(3):199\u2013206.","journal-title":"Pract Neurol."},{"issue":"1","key":"875_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","volume":"13","author":"JT Guptill","year":"2016","unstructured":"Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016;13(1):118\u201331.","journal-title":"Neurotherapeutics."},{"key":"875_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30363-0","author":"NE Gilhus","year":"2017","unstructured":"Gilhus NE. Eculizumab: a treatment option for mysthenia gravis? Lancet Neurol. 2017. https:\/\/doi.org\/10.1016\/S1474-4422(17)30363-0.","journal-title":"Lancet Neurol."},{"key":"875_CR39","unstructured":"Medicines Complete. Eculizumab. 2017. https:\/\/www.medicinescomplete.com\/mc\/bnf\/current\/DMD11812511000001108.htm?q=eculizumab&t=search&ss=text&tot=2&p=2#DMD11812511000001108. Accessed 24 Nov 2017."}],"updated-by":[{"DOI":"10.1007\/s40265-018-0889-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-0875-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:14:52Z","timestamp":1724411692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-0875-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0875-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"12 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Eculizumab: A Review in Generalized Myasthenia Gravis, written by Sohita\u00a0Dhillon, was originally published Online First without open access","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.Additional information about this Adis Drug Review can be found at .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}